ストックスクリーナーアプリを入手
17.92
10.41%
1.69
アフターアワーズ：
18.05
0.13
+0.73%
前日終値:
$16.23
開ける：
$17.39
24時間の取引高:
9.34M
Relative Volume:
4.44
時価総額：
$1.87B
収益：
-
当期純損益:
$-238.77M
株価収益率:
-0.6685
EPS:
-26.808
ネットキャッシュフロー:
$-216.62M
1週間 パフォーマンス:
+83.61%
1か月 パフォーマンス:
+61.15%
6か月 パフォーマンス:
+441.39%
1年 パフォーマンス:
+122.61%
1日の値動き範囲:
$16.70
$18.57
1週間の範囲:
$7.85
$22.30
52週間の値動き範囲:
$2.7601
$22.30
Alumis Inc Stock (ALMS) Company Profile
ALMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
17.92 | 1.69B | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | 再開されました | Guggenheim | Buy |
| 2025-01-30 | 開始されました | Oppenheimer | Outperform |
| 2024-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 開始されました | Guggenheim | Buy |
| 2024-07-23 | 開始されました | Leerink Partners | Outperform |
| 2024-07-23 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Alumis Inc (ALMS) 最新ニュース
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies - Yahoo Finance
Should You Chase the Rally in Alumis Stock Today? - Barchart.com
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS) - Seeking Alpha
Biopharma firm Alumis extends gains after commencing $175 mln stock offering - TradingView — Track All Markets
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential - Stocktwits
Guggenheim raises Alumis stock price target to $32 on positive trial data - Investing.com
Why Alumis Stock Spiked Almost 100% Yesterday - TIKR.com
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential - MSN
Should You Jump Into the Alumis Stock Rally Now? - Bitget
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | - GuruFocus
Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Assessing Alumis (ALMS) Valuation After Positive Envudeucitinib Phase 3 Trial Success - simplywall.st
Alumis plans $175 million common stock offering By Investing.com - Investing.com Nigeria
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Alumis’ TYK2 envu in view as standout in psoriasis phase III - BioWorld MedTech
Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval - The Business Journals
Alumis Looks To Come From Behind In TYK2 Race - Citeline News & Insights
Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily
Alumis Announces Proposed Public Offering of Common Stock - The Manila Times
Biotech Alumis plans $175M stock sale in new public offering - Stock Titan
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | ALMS Stock News - GuruFocus
Alumis Inc.: Is It Too Late To Buy? - StocksToTrade
Oppenheimer raises Alumis stock price target to $50 on positive trial results - Investing.com UK
Dow Jumps Over 400 Points; US Services Activity Falls In December - Benzinga
Alumis posts late-stage trial successes for TYK2 inhibitor in plaque psoriasis - FirstWord
Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive
Alumis (NASDAQ:ALMS) Sets New 12-Month HighWhat's Next? - MarketBeat
Alumis Skin Medication Demonstrates Significant Advantages in Advanced Trials, Shares Surge - Bitget
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval - Endpoints News
Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026 - MarketBeat
Baird raises Alumis stock price target to $35 on strong psoriasis trial data - Investing.com Canada
Alumis Stock Hits Record High on Psoriasis Drug Trial Results - Schaeffer's Investment Research
Alumis price target raised to $39 from $17 at Wells Fargo - TipRanks
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
Alumis (ALMS) Stock: Clinical Trial Results Send Shares Up 60% on Tuesday - Blockonomi
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high - TechStock²
Alumis surges on late-stage trial win for lead drug in plaque psoriasis - Seeking Alpha
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is ALMS stock rising today? - MSN
US Stocks Mixed; Nasdaq Gains Over 50 Points - Benzinga
Crypto: Alumis Inc. Explodes 113.96% – The Hidden Forces Behind This Stunning Rally! - InteractiveCrypto
Why Is ALMS Stock Rising Today? - Stocktwits
Crypto: Alumis Inc's Explosive 113.96% Surge: The Secrets Behind the Stunning Rally - InteractiveCrypto
Alumis Shares Surge After Plaque Psoriasis Drug Trials Meet Endpoints - MarketWatch
Alumis shares surge to record high as skin disease drug aces late-stage trials - MarketScreener
Alumis stock soars after drug shows strong psoriasis results in Phase 3 By Investing.com - Investing.com South Africa
Alumis stock soars after drug shows strong psoriasis results in Phase 3 - Investing.com Australia
Alumis Inc (ALMS) 財務データ
収益
当期純利益
現金流量
EPS
28.63%
大文字化:
|
ボリューム (24 時間):